These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8567966)

  • 21. Intrafamilial variable expressivity of osteogenesis imperfecta due to mosaicism for a lethal G382R substitution in the COL1A1 gene.
    Cohen-Solal L; Zolezzi F; Pignatti PF; Mottes M
    Mol Cell Probes; 1996 Jun; 10(3):219-25. PubMed ID: 8799376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemical cleavage method for the detection of RNA base changes: experience in the application to collagen mutations in osteogenesis imperfecta.
    Bateman JF; Lamande SR; Hannagan M; Moeller I; Dahl HH; Cole WG
    Am J Med Genet; 1993 Jan; 45(2):233-40. PubMed ID: 8456808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteogenesis imperfecta: prospects for molecular therapeutics.
    Forlino A; Marini JC
    Mol Genet Metab; 2000; 71(1-2):225-32. PubMed ID: 11001814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative modulation of alpha1(I) procollagen gene expression in human skin fibroblasts: transcriptional inhibition by interferon-gamma.
    Yuan W; Yufit T; Li L; Mori Y; Chen SJ; Varga J
    J Cell Physiol; 1999 Apr; 179(1):97-108. PubMed ID: 10082137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Attempts to use gene therapy for reducing connective tissue disorders--osteogenesis imperfecta].
    Gajko-Galicka A
    Postepy Biochem; 2003; 49(1):18-25. PubMed ID: 14518394
    [No Abstract]   [Full Text] [Related]  

  • 26. Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy.
    Kollberg G; Holme E
    Neuromuscul Disord; 2009 Dec; 19(12):833-6. PubMed ID: 19846308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense oligonucleotide inhibits the expression of procollagen type III gene in mouse fibroblasts.
    Kitamura Y; Tanigawa T; Nanba E; Ueno E; Fukumoto S; Ichihara K
    Biochem Biophys Res Commun; 1995 Oct; 215(3):849-54. PubMed ID: 7488051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease.
    Rodríguez-Pascau L; Coll MJ; Vilageliu L; Grinberg D
    Hum Mutat; 2009 Nov; 30(11):E993-E1001. PubMed ID: 19718781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of human type III collagen gene expression by antisense oligodeoxynucleotide.
    Jia F; Shimomura T; Niyibizi C; Woo SL
    Tissue Eng; 2005; 11(9-10):1429-35. PubMed ID: 16259598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
    Spiller DG; Giles RV; Broughton CM; Grzybowski J; Ruddell CJ; Tidd DM; Clark RE
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):281-93. PubMed ID: 9743466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Photodynamic antisense regulation of mRNA having a point mutation with psoralen-conjugated oligonucleotide.
    Higuchi M; Yamayoshi A; Kobori A; Murakami A
    Nucleic Acids Symp Ser (Oxf); 2008; (52):515-6. PubMed ID: 18776480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta.
    Redford-Badwal DA; Stover ML; Valli M; McKinstry MB; Rowe DW
    J Clin Invest; 1996 Feb; 97(4):1035-40. PubMed ID: 8613526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Suppression of influenza virus NP-protein mRNA translation in vitro with derivatives of an antisense oligonucleotide].
    Abramova TV; Vlasov VV; Ivanova EM; Zarytova VF; Fokina TN; Frolova EI; Iurchenko LV
    Mol Biol (Mosk); 1994; 28(2):307-12. PubMed ID: 8183262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delivery of a hammerhead ribozyme specifically downregulates mutant type I collagen mRNA in a murine model of osteogenesis imperfecta.
    Toudjarska I; Kilpatrick MW; Niu J; Wenstrup RJ; Tsipouras P
    Antisense Nucleic Acid Drug Dev; 2001 Oct; 11(5):341-6. PubMed ID: 11763351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A mutation-independent therapeutic strategem for osteogenesis imperfecta.
    Millington-Ward S; O'Neill B; Kiang AS; Humphries P; Kenna PF; Farrar GJ
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):537-42. PubMed ID: 10645780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tracking COL1A1 RNA in osteogenesis imperfecta. splice-defective transcripts initiate transport from the gene but are retained within the SC35 domain.
    Johnson C; Primorac D; McKinstry M; McNeil J; Rowe D; Lawrence JB
    J Cell Biol; 2000 Aug; 150(3):417-32. PubMed ID: 10931857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense oligonucleotides reduce synthesis of procollagen alpha1 (V) chain in human patellar tendon fibroblasts: potential application in healing ligaments and tendons.
    Shimomura T; Jia F; Niyibizi C; Woo SL
    Connect Tissue Res; 2003; 44(3-4):167-72. PubMed ID: 14504037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approaches for skeletal gene therapy.
    Niyibizi C; Wallach CJ; Mi Z; Robbins PD
    Crit Rev Eukaryot Gene Expr; 2002; 12(3):163-73. PubMed ID: 12449341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An intron mutation in the human alpha 1(I) collagen gene alters the efficiency of pre-mRNA splicing and is associated with osteogenesis imperfecta type II.
    Bonadio J; Ramirez F; Barr M
    J Biol Chem; 1990 Feb; 265(4):2262-8. PubMed ID: 2298750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential of gene therapy for treating osteogenesis imperfecta.
    Niyibizi C; Smith P; Mi Z; Robbins P; Evans C
    Clin Orthop Relat Res; 2000 Oct; (379 Suppl):S126-33. PubMed ID: 11039761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.